Company · CIK 2020932
AgomAb Therapeutics NV
| CIK | 2020932 (SEC EDGAR) |
|---|---|
| Industry (SIC) | 2836 — Biological Products, (No Diagnostic Substances) |
| Incorporated in | C9 |
| Listed | AGMB (Nasdaq) |
| First annual or quarterly report | 2026-04-23 |
Offerings
1 registration| Registration | Label and status | First filed | Last event | Filings |
|---|---|---|---|---|
| 333-292790 | 2026-01-16 | 2026-02-06 | 4 |
Filings
5| Filed | Filing | Registration | Accession |
|---|---|---|---|
| 2026-02-06 | 424B4Final prospectus | 333-292790 | 0001104659-26-011523 |
| 2026-01-30 | EFFECTDeclared effective | 333-292790 | 9999999995-26-000416 |
| 2026-01-29 | F-1/AAmendment | 333-292790 | 0001104659-26-007712 |
| 2026-01-16 | F-1Registration filed | 333-292790 | 0001104659-26-004558 |
| 2024-06-20 | DRSDraft made public | 377-07291 | 0001104659-24-073452 |